Crohn's Disease

Clinical Trials

Below is a list of Crohn's Disease clinical trials from the clinical trials database at Mayo Clinic.

This list includes only trials about which Mayo researchers choose to publish information. Mayo Clinic may be conducting other trials which are not in this database. Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

Abatacept for the treatment of subjects with active Crohn's disease
The purpose of this study is to see if the investigational use of abatacept is better than placebo (inactive substance) for the treatment of active Crohn's disease. Abatacept was approved by the United States Food and Drug Administration (FDA) in December 2005 for the treatment of rheumatoid arthritis in the United States and in June 2006 in Canada. The use of abatacept remains investigational for other diseases. An investigational use in one that is not yet approved by the regulatory authorities such as the FDA.

A second purpose of this study is to evaluate the safety (possible side effects) of abatacept in patients with Crohn's disease.
Read more

Certolizumab Pegol for the treatment of Crohn's Disease
This study is being done to see what effects (good and bad) an experimental drug, certolizumab pegol, has in treating patients with Crohn's disease compared with placebo. This study is also to look at whether or not patients currently taking corticosteroid are able to gradually stop taking them.

Certolizumab pegol is an anti-TNF, humanized antibody which works by blocking an inflammatory substance in the body that is called tumor necrosis factor (TNF).
Read more